(2002) “The interferon system: an overview”, European Journal of Paediatric Neurology6 Suppl A (6), p. A41–6; discussion A55–8. doi:10.1053/ejpn.2002.0573. 4523675.
(Novembro 2021) “Innate Immune Antagonism of Mosquito-Borne Flaviviruses in Humans and Mosquitoes”, Viruses (en) 13 (11), p. 2116. doi:10.3390/v13112116.
(2000) “Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review”, Health Technology Assessment4 (33), p. 1–67. doi:10.3310/hta4330.
(2012) “Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection”, Therapeutic Advances in Gastroenterology5 (2), p. 139–151. doi:10.1177/1756283X11426895.
(2011) “Boceprevir for Untreated Chronic HCV Genotype 1 Infection”, New England Journal of Medicine364 (13), p. 1195–1206. doi:10.1056/NEJMoa1010494.
(2011) “Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection”, New England Journal of Medicine364 (13), p. 1207–1217. doi:10.1056/NEJMoa1009482.
(2013) “Sofosbuvir for previously untreated chronic hepatitis C infection”, New England Journal of Medicine368 (20), p. 1878–1887. doi:10.1056/NEJMoa1214853.